<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01262300</url>
  </required_header>
  <id_info>
    <org_study_id>10-0189</org_study_id>
    <secondary_id>K23AG040708</secondary_id>
    <nct_id>NCT01262300</nct_id>
  </id_info>
  <brief_title>Vitamin D Supplementation And Varicella Zoster Virus Vaccine Responsiveness In Older Long-Term Care Residents</brief_title>
  <official_title>Vitamin D Supplementation And Varicella Zoster Virus Vaccine Responsiveness In Older Nursing Home Residents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an ancillary study to a randomized controlled trial of high dose vitamin D in older&#xD;
      long-term care residents (NCT01102374). In this study, a subset of trial subjects will&#xD;
      receive the zoster vaccine and the investigators will determine the immunological response to&#xD;
      the vaccine in this older, frail population, as well as the association between vitamin D and&#xD;
      immunological outcomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives&#xD;
&#xD;
        1. To determine the increase in Varicella-zoster virus (VZV)-specific cell-mediated immune&#xD;
           response from pre-zoster vaccination to 3 weeks post-vaccination in nursing home&#xD;
           residents after 4 months of high dose vs. standard dose vitamin D3 supplementation.&#xD;
&#xD;
        2. In the same participants as Aim 1, to measure the association between pre-zoster&#xD;
           vaccination 25-hydroxyvitamin D [25(OH)D] levels and the increase in VZV-specific&#xD;
           cell-mediated immune response from pre- vaccination to 3 weeks post-vaccination.&#xD;
&#xD;
        3. Characterize the phenotypic and functional VZV-specific T cell responses to Zostavax,&#xD;
           including memory, effector, Th1/Th2, and homing receptor-bearing T cells in the high&#xD;
           compared to low ELISPOT responders.&#xD;
&#xD;
      Hypotheses&#xD;
&#xD;
        1. At baseline, higher serum 25(OH)D levels will be associated with higher levels of&#xD;
           VZV-specific cell-mediated immunity (cross-sectional).&#xD;
&#xD;
        2. At baseline, higher serum 25(OH)D levels, independent of vitamin D supplementation dose,&#xD;
           will be associated with greater increases in VZV-specific cell-mediated immune responses&#xD;
           to Zostavax, as measured by the interferon (IFN)-γ ELISPOT assay.&#xD;
&#xD;
        3. Compared to standard dose, high dose vitamin D3 supplementation will enhance&#xD;
           VZV-specific cell-mediated immune response to vaccination independent of baseline serum&#xD;
           25(OH)D levels.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">January 23, 2014</completion_date>
  <primary_completion_date type="Actual">January 23, 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>VZV-specific cell mediated immunity, as measured by the interferon-γ ELISPOT assay</measure>
    <time_frame>3 weeks post-vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>VZV-gpELISA to measure the VZV-specific antibody concentration</measure>
    <time_frame>3 weeks post-vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VZV-specific effector and memory T cells</measure>
    <time_frame>3 weeks post-vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>-specific cell mediated immunity, as measured by the responder cell frequency assay</measure>
    <time_frame>3 weeks post-vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Immunosenescence</condition>
  <condition>Shingles</condition>
  <arm_group>
    <arm_group_label>VZV vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Varicella Zoster Virus vaccine (Zostavax), single dose X 1 injection&#xD;
All subjects in this trial will receive the VZV vaccine. The Investigators will primarily compare immune responses in those that are receiving high dose vs. standard dose vitamin D supplementation and those that have high and low 25-hydroxyvitamin D levels.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Varicella Zoster Virus Vaccine (Zostavax)</intervention_name>
    <description>Single 0.65 mL subcutaneous injection of the live, attenuated VZV zoster vaccine (Zostavax; Merck, Whitehouse Station, NJ).</description>
    <arm_group_label>VZV vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged ≥ 60 years;&#xD;
&#xD;
          2. Residing in a long-term care facility;&#xD;
&#xD;
          3. Have not yet received VZV vaccine&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. terminal illness (expected survival &lt;6 months);&#xD;
&#xD;
          2. anticipated discharge within 12 months;&#xD;
&#xD;
          3. unable to take whole or crushed tablets;&#xD;
&#xD;
          4. active cancer, except squamous/basal cell carcinoma;&#xD;
&#xD;
          5. severe malnutrition (body mass index &lt;18 kg/m2);&#xD;
&#xD;
          6. current immunosuppressive medications (including corticosteroids);&#xD;
&#xD;
          7. renal failure (eGFR&lt;15 mL/min/1.73m2);&#xD;
&#xD;
          8. currently taking &gt;800 IU/d vitamin D supplementation;&#xD;
&#xD;
          9. history (or strong family history) of kidney stones;&#xD;
&#xD;
         10. history of sarcoidosis or other granulomatous disorders associated with hypercalcemia;&#xD;
&#xD;
         11. elevated baseline hypercalcemia (albumin-adjusted serum calcium &gt;10.5 mg/dL);&#xD;
&#xD;
         12. serum 25 (OH)D level ≥40 ngl/ml at baseline;&#xD;
&#xD;
         13. inability to provide informed consent and no available healthcare proxy;&#xD;
&#xD;
         14. inability of participant or proxy to speak/understand English.&#xD;
&#xD;
         15. previous receipt of the Zostavax (anticipate &lt;10% of trial;&#xD;
&#xD;
         16. known allergy to gelatin, neomycin, or any other component of the vaccine.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adit A Ginde, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>A randomized controlled trial of high dose vitamin D in older long-term care residents (NCT01102374)</citation>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>December 15, 2010</study_first_submitted>
  <study_first_submitted_qc>December 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2010</study_first_posted>
  <last_update_submitted>June 23, 2021</last_update_submitted>
  <last_update_submitted_qc>June 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunosenescence</keyword>
  <keyword>Shingles</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>Varicella Zoster Virus</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Immune Response</keyword>
  <keyword>Geriatrics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Zoster</mesh_term>
    <mesh_term>Chickenpox</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

